Transforming growth factor β receptor type II inactivation promotes the establishment and progression of colon cancer

Cancer Research

Volumn 64, Issue 14, 2004, Pages 4687-4692

  Biswas, Swati ^a   Chytil, Anna ^a   Washington, Kay ^a   Romero Gallo, Judith ^a   Gorska, Agnieszka E ^a   Wirth, Pamela S ^a   Gautam, Shiva ^c   Moses, Harold L ^a   Grady, William M ^a,b,d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RECEPTOR SUBTYPE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; COLON MUCOSA; GENE MUTATION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; TGFBR2 GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; AZOXYMETHANE; CARCINOGENS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; COLON; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY ACID-BINDING PROTEINS; FEMALE; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; ISOENZYMES; MALE; MICE; MUTATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 3142664714     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3255     Document Type: Article

References (30)

1. Grady W, Myeroff L, Swinler S, et al. Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res 1999;59: 320-4.
2. Markowitz S, Roberts A. Tumor supressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev 1996;7:93-102.
3. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002;12:22-9.
4. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Investig 2002;109:1607-15.
5. Hahm KB, Lee KM, Kim YB, et al. Conditional loss of TGF-beta signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment Pharmacol Ther 2002;16(Suppl 2):115-27.
6. Tang B, Bottinger EP, Jakowlew SB, et al. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 1998;4:802-7.
7. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-206.
8. Chytil A, Magnuson MA, Wright CV, Moses HL. Conditional inactivation of the TGF-beta type II receptor using Cre:Lox. Genesis 2002;32:73-5.
9. Wong MH, Saam JR, Stappenbeck TS, Rexer CH, Gordon JI. Genetic mosaic analysis based on Cre recombinase and navigated laser capture microdissection. Proc Natl Acad Sci USA 2000;97:12601-6.
10. Saam JR, Gordon JI. Inducible gene knockouts in the small intestinal and colonic epithelium. J Biol Chem 1999;274:38071-82.
11. Taketo M, Schroeder AC, Mobraaten LE, et al. FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci USA 1991;88:2065-9.
12. Boivin GP, Washington K, Yang K, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003;124:762-77.
13. Joseph H, Gorska AE, Sohn P, Moses HL, Serra R. Overexpression of a kinase-deficient transforming growth factor-beta type II receptor in mouse mammary stroma results in increased epithelial branching. Mol Biol Cell 1999;10:1221-34.
14. Manam S, Nichols WW. Multiplex polymerase chain reaction amplification and direct sequencing of homologous sequences: point mutation analysis of the ras genes. Anal Biochem 1991;199:106-11.
15. Grady W, Rajput A, Myeroff L, et al. Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998;58:3101-4.
16. Barnard JA, Warwick GJ, Gold LI. Localization of transforming growth factor β isoforms in the normal murine small intestine and colon. Gastroenterology 1993;105:67-73.
17. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996;110:1259-62.
18. Jacoby RF, Llor X, Teng BB, Davidson NO, Brasitus TA. Mutations in the K-ras oncogene induced by 1,2-dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa. J Clin Investig 1991;87:624-30.
19. Yamada Y, Oyama T, Hirose Y, et al. Beta-catenin mutation is selected during malignant transformation in colon carcinogenesis. Carcinogenesis (Lond) 2003;24:91-7.
20. Wang CY, Eshleman JR, Willson JK, Markowitz S. Both transforming growth factor-beta and substrate release are inducers of apoptosis in a human colon adenoma cell line. Cancer Res 1995;55:5101-5.
21. Markowitz S, Myeroff L, Cooper M, et al. A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene. J Clin Investig 1994;93:1005-13.
22. Engle S, Hoying J, Boivin G, et al. Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage in tumorigenesis. Cancer Res 1999;59: 3379-86.
23. Engle SJ, Ormsby I, Pawlowski S, et al. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res 2002;62:6362-6.
24. Hahm KB, Im YH, Parks TW, et al. Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 2001;49:190-8.
25. Dumont N, Arteaga CL. A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells. Biochem Biophys Res Commun 2003;301: 108-12.
26. Luceri C, De Filippo C, Caderni G, et al. Detection of somatic DNA alterations in azoxymethane-induced F344 rat colon tumors by random amplified polymorphic DNA analysis. Carcinogenesis (Lond) 2000;21:1753-6,
27. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 1996;39:87-92.
28. Hallbook O, Boeryd B, Lilja I, Sjodahl R. Association between permeability of the colonic wall and azoxymethane induced cancer of the colon in rats. Eur J Surg 1992;158:491-4.
29. Zhu Y, Richardson J, Parada L, Graff J. Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998;94:703-14.
30. Takaku K, Oshima M, Miyoshi H, et al. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998;92:645-56.